The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
K. P. Papadopoulos
Research Funding - Onyx
D. S. Mendelson
Research Funding - Premiere Oncology
A. W. Tolcher
Consultant or Advisory Role - Amgen (U); Bayer (U); Exelixis (U); Genentech (U); Millennium (U); Novartis (U)
Honoraria - Amgen; Bayer; Exelixis; Genentech; Novartis
Research Funding - Abbott Laboratories; Amgen; Astellas Pharma; Bayer; Millennium; Onyx
A. Patnaik
Research Funding - Onyx
H. A. Burris
No relevant relationships to disclose
D. W. Rasco
Research Funding - Onyx
J. C. Bendell
No relevant relationships to disclose
M. S. Gordon
Research Funding - Onyx
G. Kato
No relevant relationships to disclose
H. Wong
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
D. Bomba
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
S. Lee
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
H. H. Gillenwater
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
T. Woo
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
J. R. Infante
No relevant relationships to disclose